Rtw Investments, LP Protagonist Therapeutics, Inc Transaction History
Rtw Investments, LP
- $6.1 Billion
- Q1 2025
A detailed history of Rtw Investments, LP transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Rtw Investments, LP holds 5,719,415 shares of PTGX stock, worth $310 Million. This represents 4.53% of its overall portfolio holdings.
Number of Shares
5,719,415
Previous 5,498,545
4.02%
Holding current value
$310 Million
Previous $212 Million
30.32%
% of portfolio
4.53%
Previous 3.46%
Shares
19 transactions
Others Institutions Holding PTGX
# of Institutions
299Shares Held
61.3MCall Options Held
1.01MPut Options Held
555K-
Farallon Capital Management LLC San Francisco, CA6.11MShares$331 Million1.7% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$312 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.28MShares$232 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT3MShares$163 Million5.07% of portfolio
-
State Street Corp Boston, MA2.71MShares$147 Million0.01% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.66B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...